Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease | Latest News RSS feed

Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease - Latest News


FOIU 2018: Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitors Era: The CARMENA Study

Mejean notes that the CARMENA trial sought to answer the question of whether or not CN is beneficial in the group of patients with a moderate amount of metastatic disease ... should no longer be consi... read more

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

XTANDI was first approved by the FDA in 2012 for the treatment of patients with metastatic ... at the 2018 Genitourinary Cancers Symposium (ASCO GU) in February and published in the New England Journa... read more

FDA Approves Xtandi for Non-Metastatic Castration-Resistant Prostate Cancer

The Food and Drug Administration (FDA) has approved Xtandi (enzalutamide) for the treatment of patients with ... and the onset of metastatic disease,“ said Jonathan Simons, M.D., Prostate Cancer Found... read more

Looking for another news?


Oncolytics: Significant Pipeline Value In The Fastest Growing Area Of Oncology

This final pivotal phase 3 study would include only (HR+/HER2-) metastatic breast cancer patients. Patients would be treated with Reolysin (pelareorep) in combination with paclitaxel with a primary en... read more


The National Comprehensive Cancer Network (NCCN) Guidelines Reco - KAIT Jonesboro, AR - Region 8 News, weather, sports

The U.S. Food and Drug Administration (FDA) approved BRAFTOVI in combination with MEKTOVI on June 27, 2018 for the treatment of patients with unresectable or metastatic melanoma ... Warnings and Preca... read more

FOIU 2018: Agonists vs. Antagonists: Should Antagonists be the Primary Choice for ADT? - YES

Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition ... LHRH-agonist and LHRH antagonist treatment in patients with ... read more

Genomic Landscape of Metastatic Prostate Cancer Unveiled in New Study

As reported in the July 19, 2018 issue of ... help prostate cancer patients in whom the BRCA DNA-repair genes are affected, said Feng, who believes the data from the new study offer new leads for the ... read more

Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future Directions

serial monitoring of cardiac function should occur at baseline; 3, 6, and 9 months during treatment; and at 12 and 18 months after initiation of therapy. For patients with metastatic disease, the pane... read more

Celgene Reports Positive Data on Tecentriq, Abraxane Study

The study met its co-primary endpoint of progression ... significantly reduced the risk of disease worsening or death (PFS) in patients with metastatic or unresectable locally advanced TNBC in the int... read more

U.S. FDA Approves Xtandi for Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer

XTANDI was first approved by the FDA in 2012 for the treatment of patients with metastatic ... the 2018 Genitourinary Cancers Symposium (ASCO GU) in February and published in the New England Journal o... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us